Search Results - "Skoulidis, Ferdinandos"

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy by Skoulidis, Ferdinandos, Heymach, John V.

“…The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for oncogene-addicted subgroups of non-small-cell lung cancer (for…”
Get full text

Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer by Skoulidis, Ferdinandos, Papadimitrakopoulou, Vassiliki A

“…In 2015, the FDA approved an unprecedented number of new therapies for non-small cell lung cancer (NSCLC), among them therapies addressing specific genomic…”
Get full text

Structure-based classification predicts drug response in EGFR-mutant NSCLC by Robichaux, Jacqulyne P., Le, Xiuning, Vijayan, R. S. K., Hicks, J. Kevin, Heeke, Simon, Elamin, Yasir Y., Lin, Heather Y., Udagawa, Hibiki, Skoulidis, Ferdinandos, Tran, Hai, Varghese, Susan, He, Junqin, Zhang, Fahao, Nilsson, Monique B., Hu, Lemei, Poteete, Alissa, Rinsurongkawong, Waree, Zhang, Xiaoshan, Ren, Chenghui, Liu, Xiaoke, Hong, Lingzhi, Zhang, Jianjun, Diao, Lixia, Madison, Russell, Schrock, Alexa B., Saam, Jennifer, Raymond, Victoria, Fang, Bingliang, Wang, Jing, Ha, Min Jin, Cross, Jason B., Gray, Jhanelle E., Heymach, John V.

“…Epidermal growth factor receptor ( EGFR ) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC) 1…”
Get full text

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status by Ricciuti, Biagio, Arbour, Kathryn C, Lin, Jessica J, Vajdi, Amir, Vokes, Natalie, Hong, Lingzhi, Zhang, Jianjun, Tolstorukov, Michael Y, Li, Yvonne Y, Spurr, Liam F, Cherniack, Andrew D, Recondo, Gonzalo, Lamberti, Giuseppe, Wang, Xinan, Venkatraman, Deepti, Alessi, Joao V, Vaz, Victor R, Rizvi, Hira, Egger, Jacklynn, Plodkowski, Andrew J, Khosrowjerdi, Sara, Digumarthy, Subba, Park, Hyesun, Vaz, Nuno, Nishino, Mizuki, Sholl, Lynette M, Barbie, David, Altan, Mehmet, Heymach, John V, Skoulidis, Ferdinandos, Gainor, Justin F, Hellmann, Matthew D, Awad, Mark M

“…STK11 and KEAP1 mutations (STK11 mutant [STK11 ] and KEAP1 ) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 has been…”
Get more information

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition by Mak, Milena P, Tong, Pan, Diao, Lixia, Cardnell, Robert J, Gibbons, Don L, William, William N, Skoulidis, Ferdinandos, Parra, Edwin R, Rodriguez-Canales, Jaime, Wistuba, Ignacio I, Heymach, John V, Weinstein, John N, Coombes, Kevin R, Wang, Jing, Byers, Lauren Averett

“…We previously demonstrated the association between epithelial-to-mesenchymal transition (EMT) and drug response in lung cancer using an EMT signature derived…”
Get full text

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study by Gomez, Daniel R, Dr, Blumenschein, George R, Prof, Lee, J Jack, Prof, Hernandez, Mike, MS, Ye, Rong, MS, Camidge, D Ross, Prof, Doebele, Robert C, MD, Skoulidis, Ferdinandos, MD, Gaspar, Laurie E, Prof, Gibbons, Don L, MD, Karam, Jose A, MD, Kavanagh, Brian D, Prof, Tang, Chad, MD, Komaki, Ritsuko, Prof, Louie, Alexander V, MD, Palma, David A, MD, Tsao, Anne S, MD, Sepesi, Boris, MD, William, William N, MD, Zhang, Jianjun, MD, Shi, Qiuling, PhD, Wang, Xin Shelley, MD, Swisher, Stephen G, Prof, Heymach, John V, Prof

“…Summary Background Evidence from retrospective studies suggests that disease progression after first-line chemotherapy for metastatic non-small-cell lung…”
Get full text

CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade by Chen, Limo, Diao, Lixia, Yang, Yongbin, Yi, Xiaohui, Rodriguez, B Leticia, Li, Yanli, Villalobos, Pamela A, Cascone, Tina, Liu, Xi, Tan, Lin, Lorenzi, Philip L, Huang, Anfei, Zhao, Qiang, Peng, Di, Fradette, Jared J, Peng, David H, Ungewiss, Christin, Roybal, Jonathon, Tong, Pan, Oba, Junna, Skoulidis, Ferdinandos, Peng, Weiyi, Carter, Brett W, Gay, Carl M, Fan, Youhong, Class, Caleb A, Zhu, Jingfen, Rodriguez-Canales, Jaime, Kawakami, Masanori, Byers, Lauren Averett, Woodman, Scott E, Papadimitrakopoulou, Vassiliki A, Dmitrovsky, Ethan, Wang, Jing, Ullrich, Stephen E, Wistuba, Ignacio I, Heymach, John V, Qin, F Xiao-Feng, Gibbons, Don L

“…Although treatment with immune checkpoint inhibitors provides promising benefit for patients with cancer, optimal use is encumbered by high resistance rates…”
Get more information

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations by Remon, Jordi, Passiglia, Francesco, Ahn, Myung-Ju, Barlesi, Fabrice, Forde, Patrick M, Garon, Edward B, Gettinger, Scott, Goldberg, Sarah B, Herbst, Roy S, Horn, Leora, Kubota, Kaoru, Lu, Shun, Mezquita, Laura, Paz-Ares, Luis, Popat, Sanjay, Schalper, Kurt A, Skoulidis, Ferdinandos, Reck, Martin, Adjei, Alex A, Scagliotti, Giorgio V

“…In the past 10 years, a deeper understanding of the immune landscape of cancers, including immune evasion processes, has allowed the development of a new class…”
Get more information

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial by Welsh, James, Menon, Hari, Chen, Dawei, Verma, Vivek, Tang, Chad, Altan, Mehmet, Hess, Kenneth, de Groot, Patricia, Nguyen, Quynh-Nhu, Varghese, Rejani, Comeaux, Nathan I, Simon, George, Skoulidis, Ferdinandos, Chang, Joe Y, Papdimitrakopoulou, Vasiliki, Lin, Steven H, Heymach, John V

“…BackgroundIn this phase I/II trial, we evaluated the safety and effectiveness of pembrolizumab, with or without concurrent radiotherapy (RT), for lung and…”
Get full text

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer by Negrao, Marcelo V, Skoulidis, Ferdinandos, Montesion, Meagan, Schulze, Katja, Bara, Ilze, Shen, Vincent, Xu, Hao, Hu, Sylvia, Sui, Dawen, Elamin, Yasir Y, Le, Xiuning, Goldberg, Michael E, Murugesan, Karthikeyan, Wu, Chang-Jiun, Zhang, Jianhua, Barreto, David S, Robichaux, Jacqulyne P, Reuben, Alexandre, Cascone, Tina, Gay, Carl M, Mitchell, Kyle G, Hong, Lingzhi, Rinsurongkawong, Waree, Roth, Jack A, Swisher, Stephen G, Lee, Jack, Tsao, Anne, Papadimitrakopoulou, Vassiliki, Gibbons, Don L, Glisson, Bonnie S, Singal, Gaurav, Miller, Vincent A, Alexander, Brian, Frampton, Garrett, Albacker, Lee A, Shames, David, Zhang, Jianjun, Heymach, John V

“…BackgroundNon-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade…”
Get full text

Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer by Tang, Ke-Jing, Constanzo, Jerfiz D, Venkateswaran, Niranjan, Melegari, Margherita, Ilcheva, Mariya, Morales, Julio C, Skoulidis, Ferdinandos, Heymach, John V, Boothman, David A, Scaglioni, Pier Paolo

“…Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide due to the limited availability of effective therapeutic options…”
Get full text

Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients with Solid Tumors by Yibirin, Marcel, Mustafayev, Khalis, Hosry, Jeff, Pundhir, Pooja, Klingen, Joseph, Guevara, Eduardo Yepez, Granwehr, Bruno P., Kaseb, Ahmed, Naing, Aung, Patel, Sapna, Shah, Amishi Y., Skoulidis, Ferdinandos, Tawbi, Hussein A., Wang, Lan, Miller, Ethan, Zhang, Hao Chi, Zurita-Saavedra, Amado, Torres, Harrys A.

“…Data are scarce regarding the virologic impact and safety of immune checkpoint inhibitors (ICI) in patients with chronic hepatitis C virus (HCV) infection. We…”
Get full text

Bone morphogenetic protein 7 promotes resistance to immunotherapy by Cortez, Maria Angelica, Masrorpour, Fatemeh, Ivan, Cristina, Zhang, Jie, Younes, Ahmed I., Lu, Yue, Estecio, Marcos R, Barsoumian, Hampartsoum B., Menon, Hari, Caetano, Mauricio da Silva, Ramapriyan, Rishab, Schoenhals, Jonathan E., Wang, Xiaohong, Skoulidis, Ferdinandos, Wasley, Mark D., Calin, George, Hwu, Patrick, Welsh, James W.

“…Immunotherapies revolutionized cancer treatment by harnessing the immune system to target cancer cells. However, most patients are resistant to immunotherapies…”
Get full text

Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer by Hong, Lingzhi, Aminu, Muhammad, Li, Shenduo, Lu, Xuetao, Petranovic, Milena, Saad, Maliazurina B., Chen, Pingjun, Qin, Kang, Varghese, Susan, Rinsurongkawong, Waree, Rinsurongkawong, Vadeerat, Spelman, Amy, Elamin, Yasir Y., Negrao, Marcelo V., Skoulidis, Ferdinandos, Gay, Carl M., Cascone, Tina, Gandhi, Saumil J., Lin, Steven H., Lee, Percy P., Carter, Brett W., Wu, Carol C., Antonoff, Mara B., Sepesi, Boris, Lewis, Jeff, Gibbons, Don L., Vaporciyan, Ara A., Le, Xiuning, Jack Lee, J., Roy-Chowdhuri, Sinchita, Routbort, Mark J., Gainor, Justin F., Heymach, John V., Lou, Yanyan, Wu, Jia, Zhang, Jianjun, Vokes, Natalie I.

“…The role of combination chemotherapy with immune checkpoint inhibitors (ICI) (ICI-chemo) over ICI monotherapy (ICI-mono) in non-small cell lung cancer (NSCLC)…”
Get full text

De novo lipogenesis represents a therapeutic target in mutant Kras non‐small cell lung cancer by Singh, Anju, Ruiz, Christian, Bhalla, Kavita, Haley, John A., Li, Qing Kay, Acquaah‐Mensah, George, Montal, Emily, Sudini, Kuladeep R., Skoulidis, Ferdinandos, Wistuba, Ignacio I., Papadimitrakopoulou, Vassiliki, Heymach, John V., Boros, Laszlo G., Gabrielson, Edward, Carretero, Julian, Wong, Kwok‐Kin, Haley, John D., Biswal, Shyam, Girnun, Geoffrey D.

“…ABSTRACT Oncogenic Kras mutations are one of the most common alterations in non‐small cell lung cancer and are associated with poor response to treatment and…”
Get full text

Author Correction: Bone morphogenetic protein 7 promotes resistance to immunotherapy by Cortez, Maria Angelica, Masrorpour, Fatemeh, Ivan, Cristina, Zhang, Jie, Younes, Ahmed I., Lu, Yue, Estecio, Marcos R., Barsoumian, Hampartsoum B., Menon, Hari, da Silva Caetano, Mauricio, Ramapriyan, Rishab, Schoenhals, Jonathan E., Wang, Xiaohong, Skoulidis, Ferdinandos, Wasley, Mark D., Calin, George, Hwu, Patrick, Welsh, James W.

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations by Ruiz-Cordero, Roberto, Ma, Junsheng, Khanna, Abha, Lyons, Genevieve, Rinsurongkawong, Waree, Bassett, Roland, Guo, Ming, Routbort, Mark J, Zhang, Jianjun, Skoulidis, Ferdinandos, Heymach, John, Roarty, Emily B, Tang, Zhenya, Medeiros, L Jeffrey, Patel, Keyur P, Luthra, Rajyalakshmi, Roy-Chowdhuri, Sinchita

“…Gene expression profiling has consistently identified three molecular subtypes of lung adenocarcinoma that have prognostic implications. To facilitate…”
Get full text

Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer by Zhou, Nicolas, Leung, Cheuk H, William, Jr, William N, Weissferdt, Annikka, Pataer, Apar, Godoy, Myrna C B, Carter, Brett W, Fossella, Frank V, Tsao, Anne S, Blumenschein, George R, Le, Xiuning, Zhang, Jianjun, Skoulidis, Ferdinandos, Kurie, Jonathan M, Altan, Mehmet, Lu, Charles, Glisson, Bonnie S, Byers, Lauren A, Elamin, Yasir Y, Mehran, Reza J, Rice, David C, Walsh, Garrett L, Hofstetter, Wayne L, Roth, Jack A, Tran, Hai T, Wu, Jia, Solis Soto, Luisa M, Kadara, Humam, Swisher, Stephen G, Vaporciyan, Ara A, Gibbons, Don L, Lin, Heather Y, Lee, J Jack, Heymach, John V, Negrao, Marcelo V, Sepesi, Boris, Cascone, Tina

“…Neoadjuvant immune checkpoint inhibitors (ICIs) have improved survival outcomes compared with chemotherapy in resectable non-small cell lung cancer (NSCLC)…”
Get full text

Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial by Altan, Mehmet, Wang, Yan, Song, Juhee, Welsh, James, Tang, Chad, Guha-Thakurta, Nandita, Blumenschein, George R, Carter, Brett W, Wefel, Jeffrey S, Ghia, Amol J, Yeboa, Debra N, McAleer, Mary Frances, Chung, Caroline, Woodhouse, Kristina D, McGovern, Susan L, Wang, Chenyang, Kim, Betty Y S, Weinberg, Jeffrey S, Briere, Tina M, Elamin, Yasir Y, Le, Xiuning, Cascone, Tina, Negrao, Marcelo V, Skoulidis, Ferdinandos, Ferrarotto, Renata, Heymach, John V, Li, Jing

“…BackgroundUp to 20% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis (BM), for which the current standard of care is radiation…”
Get full text

Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor by Hattori, Hiroyoshi, Skoulidis, Ferdinandos, Russell, Paul, Venkitaraman, Ashok R

“…Inherited mutations in the tumor suppressor BRCA2 are predisposed to pancreatic adenocarcinomas, which carry activating mutations in the KRAS oncogene in more…”
Get full text